List view / Grid view
The interaction between proteins on apoptotic cells and receptors of the murine immune system prevents autoimmune reactions and could be the basis for new treatments, according to scientists.
Deletion of the BMAL1 gene causes changes to the macrophage cytoskeleton, enhancing mouse model ability to combat bacterial pneumonia infection, according to new research.
A study has revealed that activation of syndecan-4 sensory protrusions extending from cells may be a future target for cancer therapy.
A new drug-like compound has been developed which reportedly prevents the body from producing a protein that is often at the root of Parkinson's disease.
Researchers have shown that a protein therapy has been successful in pre-clinical models at improving the quality of scar tissue after heart attacks, leading to better overall heart function.
A new study could lead to medical compounds one day being introduced into cells with the help of bacterial toxin and could open up new possibilities in cancer medicine.
A mechanism has been revealed that could be used to deny RAS mutant tumour cells (which is known to encourage the growth seen in pancreatic cancer patients) of a key survival mechanism.
Chemical crosslinking coupled with mass spectrometry (XL-MS) has been used for many years to study protein structure and function. However, recent advances in MS technology, as well as crosslinking reagents and data analysis tools, mean the technique has truly come of age. Here, Albert JR Heck, Alexander Makarov, Henning Urlaub…
New research has categorised hundreds of cancers based on their common protein mutations, highlighting cell components and tumour microenvironments as possible new therapy targets.
A new chemical tool has been used to identify hundreds of modified proteins which allows new insights to major diseases.
When your work demands unique reagents or scientific support, turn to the decades of product development legacy behind Bio-Techne’s trusted brands.
Chimeric antigen receptor (CAR) T cell transfer has had success as a treatment for leukemia and lymphoma, but solid tumors have been more challenging due to the rarity of true tumor-specific target molecules and the immunosuppressive nature of the tumor microenvironment.
A study has demonstrated the success of changing the genome of mice, regulating the production of the C11orf46 gene.
Researchers have used a machine-learning algorithm to study protein appearance and discover common features that influence function, which could be used to design artificial cells.
PROTAC drugs that safely and effectively target leukaemia and lymphoma cells have been developed by researchers.
